Tag Archives: DSKYF

how to find stock price

Sensible, dependable, long-lasting.

That’s how many new-vehicle buyers would describe Toyota. But boring? That hits a little too close to home for CEO Akio Toyoda.

“Until now, there were times when Toyotas cars were called ‘boring’ or were said to be lacking in character,” Toyoda told reporters Wednesday. “But I now feel that, in terms of driving and design, our customers have begun to favorably evaluate our cars.”

Nonetheless, he acknowledged, there’s “still room for improvement.”

Toyoda’s comments came as the Japanese automaker reported so-sofinancial results for the full fiscal year ended March 31.

Because oftough currency rates, the company reported a 20.8% drop in net income to a still-robust 1.831 trillion yen, or $16.1 billion at today’s rates.

how to find stock price: Nucor Corporation(NUE)

Advisors’ Opinion:

  • [By Lee Jackson]

    This top steel company could do very well if the economy sees a solid pickup this year and the administration’s infrastructure push remainsin place. Nucor Corp. (NYSE: NUE) and its affiliates are manufacturers of steel products, with operating facilities primarily in the United States and Canada. The company alsois North America’s largest recycler.

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    AK Steel Holding Corporation (NYSE: AKS): Free Stock Analysis Report
     
    Steel Dynamics, Inc. (NASDAQ: STLD): Free Stock Analysis Report
     
    ArcelorMittal (NYSE: MT): Free Stock Analysis Report
     
    United States Steel Corporation (NYSE: X): Free Stock Analysis Report
     
    Nucor Corporation (NYSE: NUE): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

  • [By Jon C. Ogg]

    Nucor Corp. (NYSE: NUE) was raised to Buy from Neutral on Monday. Nucor was last seen trading up 1.5% at $55.73. It has a 52-week range of $44.81 to $68.00 and has a consensus analyst price target of $69.83.

  • [By Peter Graham]

    A long term performance chart shows shares of United States Steel Corporation performing better than Market Vectors Steel ETF (NYSEARCA: SLX); but now underperforming large cap Nucor Corporation (NYSE: NUE) andmid cap Steel Dynamics (NASDAQ: STLD):

  • [By Ben Levisohn]

    But U.S. Steel is getting killed, as are AK Steel (AKS), Steel Dynamics (STLD) and Nucor (NUE). Can we chalk it up to Paul Ryan’s comments that tax reform could take longer than health care reform, which also seems to be tanking the overall market?

how to find stock price: (SIOLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    China Life (NYSE:LFC) holds a 44 percent stake in China Guangfa Bank and a 30 percent stake in Sino-Ocean Group (OTCPK:SIOLF). Foresea owns large stakes in Gree Electric Appliances and China Vanke. If they are forced to sell their stakes, the Chinese stock market could see a sudden downturn.

how to find stock price: Daiichi Sankyo Company, Limited (DSKYF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    According to Bob Radie (see transcript of January 9th teleconference), the company’s president and chief executive officer, a key consideration in the denial was the FDA’s granting, in November 2016, rival product MorphaBond three-year exclusivity for the intranasal route of abuse. Significantly, though, even though MorphaBond – developed by tiny, privately-owned Inspirion Delivery Technologies – was approved in October 2015, it is yet to be commercialized. An October 25, 2016, marketing agreement between Inspirion and Japan-based Daiichi Sankyo, Inc. (OTCPK:DSKYF) suggests MorphaBond could be launched in the near future, but it’s also important to note that the aforementioned exclusivity expires on October 2, 2018, at which point Egalet will be able to include the clinical data from its intranasal abuse potential study in its label.

how to find stock price: American Tower Corporation (REIT)(AMT)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    American Tower (AMT) : “This is the best in the business and is worth owning, even if the chart looks terrible.”

    Mattel (MAT) : “I think you’re OK but I prefer Hasbro (HAS) for growth.”

ny stock exchange today

Facebook CEO Mark Zuckerberg

In 2014, Facebook Inc. (Nasdaq: FB) founder Mark Zuckerberg paid close to $100 million for 700 acres of beachfront property on the Hawaiian island of Kauai.

Now the social media multibillionaire is suing hundreds of locals in the area who still have legal ownership claims to parts of his estate through their ancestors.

Which is exactly why Zuckerberg is taking them to court

Mark Zuckerberg Sues Natives for Eight Acres of Land

Three holding companies all of which are controlled by Zuckerberg filed eight lawsuits in local court on Dec. 30, 2016, against families who collectively inherited 14 parcels of land through the Kuleana Act.

This particular legislation was established in 1850 to give – for the first time – island natives the right to own the land on which theyd lived.

ny stock exchange today: Peugeot S.A. (PUGOY)

Advisors’ Opinion:

  • [By Adam Levine-Weinberg]

    Now, the General is thinking about ditching Europe for good by selling its European operations to French automaker Peugeot (NASDAQOTH:PUGOY). As long as Peugeot is willing to pay a reasonable price, selling Opel is GM’s best course of action.

  • [By John Rosevear]

    It’s official: General Motors (NYSE:GM) will sell its long-troubled Opel subsidiary to French automaker Peugeot S.A. (NASDAQOTH:PUGOY) for about $2.3 billion, in a deal expected to close later this year.

  • [By SEEKINGALPHA.COM]

    Yes, you read that correct! General Motors (NYSE: GM) will probably not settle for just a new 52-week high and will aim to take out the 2013 peak of $41.85. With talks about the Opel sellout to PSA Group (OTCPK:PEUGF) (OTCPK:PUGOY) progressing at a rate much faster than I had anticipated, a (likely) deal announcement on Monday will pave the way for new all-time highs.

ny stock exchange today: VALE S.A.(VALE)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Mosaic (MOS) tumbled to the bottom of the S&P 500 today after announcing that it would buy Vale’s (VALE) fertilizer unit.

    Getty Images

    Mosaicdropped 1.1% to $27.77 today, while the S&P 500 advanced 0.2% to 2,262.53.

  • [By Craig Jones]

    On CNBC's Fast Money Halftime Report, Jon Najarian spoke about unusually high put options activity in Arconic Inc (NYSE: ARNC) and Vale SA (ADR) (NYSE: VALE).

ny stock exchange today: FMC Technologies, Inc.(FTI)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Following a series of M&A announcements in the oilfield-services sector since the onset of the oil market downturn, French oil-field service company Technip and U.S. oilfield equipment company FMC Technologies (NYSE:FTI) hooked up in an all-stock deal valuing the combined company at $13 billion. Shareholders of each company will own 50% of the combined entity, to be named TechnipFMC, which implies a roughly $6.5 billion acquisition valuation for each entity. The transaction, which should close early next year, will “combine Technip’s innovative systems and solutions, state-of-the-art assets, engineering strengths, and project management capabilities with FMC Technologies’ leading technology, manufacturing, and service capabilities.” Further, it should save $400 million in annual costs by 2019. Moreover, it will enable the combined company to compete better against larger oil-field service rivals Baker Hughes (NYSE:BHI), Halliburton (NYSE:HAL), and Schlumberger (NYSE:SLB), which have all gained strength during the downturn either through M&A activities or cost savings initiatives.

ny stock exchange today: (SIOLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    China Life (NYSE:LFC) holds a 44 percent stake in China Guangfa Bank and a 30 percent stake in Sino-Ocean Group (OTCPK:SIOLF). Foresea owns large stakes in Gree Electric Appliances and China Vanke. If they are forced to sell their stakes, the Chinese stock market could see a sudden downturn.

ny stock exchange today: Daiichi Sankyo Company, Limited (DSKYF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    According to Bob Radie (see transcript of January 9th teleconference), the company’s president and chief executive officer, a key consideration in the denial was the FDA’s granting, in November 2016, rival product MorphaBond three-year exclusivity for the intranasal route of abuse. Significantly, though, even though MorphaBond – developed by tiny, privately-owned Inspirion Delivery Technologies – was approved in October 2015, it is yet to be commercialized. An October 25, 2016, marketing agreement between Inspirion and Japan-based Daiichi Sankyo, Inc. (OTCPK:DSKYF) suggests MorphaBond could be launched in the near future, but it’s also important to note that the aforementioned exclusivity expires on October 2, 2018, at which point Egalet will be able to include the clinical data from its intranasal abuse potential study in its label.

investment definition

Woody Allen called the scandal looming over Harvey Weinstein, “very sad for everybody involved.” The disgraced movie mogul is facing dozens of allegations that include sexual assault and rape.

In an interview with BBC, Allen called the situation “tragic for the poor women that were involved, sad for Harvey that [his] life is so messed up.”

He told the outlet that he’d heard rumors about misconduct by Weinstein, which have swirled around the industry for decades, but he was not aware of the more serious accusations.

Weinstein, through a spokesperson, has “unequivocally” denied “any allegations of non-consensual sex.”

Allen, who has faced his own separate sexual assault allegation from his adopted daughter, also said he hopes that women speaking up will lead to “some amelioration.” But he added that he doesn’t want it to lead to a “witch hunt atmosphere … where every guy in an office who winks at a woman is suddenly having to call a lawyer to defend himself.”

investment definition: OneBeacon Insurance Group, Ltd.(OB)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

investment definition: Ono Pharmaceutical Co., Ltd. (OPHLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Merck could achieve a consistent advantage versus BMS in treatment of 1L NSCLC. There is a precise crossroad that will determine the future of these two companies in this field: the question of whether or not Keytruda will be approved in May. Both the market and investors believe that it will indeed gain approval and BMS’s stock is already paying for that. In the short term, the repercussions will be the contractions in the sales of Opdivo in 2L and a bigger obstacle for Opdivo+Yervoy in 1L. But the BMS’s combo can catch up, thanks to a bigger efficacy, as I will explain in a future article. Meanwhile, a recent trial established that Merck has to pay BMS $625M plus royalties, as it infringed BMS’s intellectual property related to the use of anti-PD1 antibodies. The royalties will be 6.5% for sales between January 2017 and the end of 2023, followed by a 2.5% rate for the period from January 2024 to the end of 2026. Bristol-Myers Squibb will share the money by giving a quarter of the amount to the Japanese Ono Pharmaceutical (OTC:OPHLF), the company which had discovered Opdivo.

investment definition: Daiichi Sankyo Company, Limited (DSKYF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    According to Bob Radie (see transcript of January 9th teleconference), the company’s president and chief executive officer, a key consideration in the denial was the FDA’s granting, in November 2016, rival product MorphaBond three-year exclusivity for the intranasal route of abuse. Significantly, though, even though MorphaBond – developed by tiny, privately-owned Inspirion Delivery Technologies – was approved in October 2015, it is yet to be commercialized. An October 25, 2016, marketing agreement between Inspirion and Japan-based Daiichi Sankyo, Inc. (OTCPK:DSKYF) suggests MorphaBond could be launched in the near future, but it’s also important to note that the aforementioned exclusivity expires on October 2, 2018, at which point Egalet will be able to include the clinical data from its intranasal abuse potential study in its label.

investment definition: Limelight Networks Inc.(LLNW)

Advisors’ Opinion:

  • [By Lisa Levin] Related Chardan Analyst Suggests An AveXis-Ionis Pair Trade Why The Biogen-Ionis News Is A Boon For AveXis AveXis' (AVXS) CEO Sean Nolan on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related CLBS Earnings Scheduled For March 17, 2017 15 Biggest Mid-Day Gainers For Thursday Caladrius Biosciences beats by $0.07, beats on revenue (Seeking Alpha) Gainers
    Caladrius Biosciences Inc (NASDAQ: CLBS) shares rose 20.2 percent to $6.13 in pre-market trading after the company reported a narrower-than-expected quarterly loss.
    Arbutus Biopharma Corp (NASDAQ: ABUS) rose 12.3 percent to $3.20 in pre-market trading after the company disclosed that it has licensed LNP delivery technology to Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for use in single messenger RNA product candidate.
    AveXis Inc (NASDAQ: AVXS) rose 12.2 percent to $81.66 in pre-market trading after the company reported topline data from Phase 1 trial of AVXS-101.
    TOP SHIPS Inc (NASDAQ: TOPS) shares rose 10.5 percent to $2.43 in pre-market trading after surging 109.52 percent on Thursday.
    ChipMOS TECHNOLOGIES INC. (NASDAQ: IMOS) rose 9.8 percent to $17.45 in pre-market trading after declining 0.44 percent on Thursday.
    Sino-Global Shipping America, Ltd. (NASDAQ: SINO) rose 8.3 percent to $3.38 in pre-market trading after climbing 23.81 percent on Thursday.
    Diana Containerships Inc (NASDAQ: DCIX) rose 7.6 percent to $2.99 in pre-market trading after surging 12.55 percent on Thursday.
    Steel Dynamics, Inc. (NASDAQ: STLD) rose 5.2 percent to $37.25 in pre-market trading. Steel Dynamics expects Q1 earnings of $0.77 to $0.81 per diluted share. The company also declared a quarterly cash dividend of $0.1550 per common share.
    Adobe Systems Incorporated (NASDAQ: ADBE)

investment definition: Cyclacel Pharmaceuticals Inc.(CYCC)

Advisors’ Opinion:

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

  • [By Alex McGuire]

    As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…

    Pharmaceutical Stock Current Share Price April 2017 Gain
    Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
    Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
    Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
    Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
    Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
    Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
    Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
    Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
    Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
    Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%

    The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.